ERBB2 and breast carcinoma: The second-line treatment with T-Dxd led to a noticeably longer OS compared to T-DM1 in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III study presented at the San Antonio Breast Cancer Symposium on 6–10 December 2022.